ImmunoGen’s First ADC For Ovarian Cancer To Exceed Sales Expectations

Stellar Launch For Elahere

ImmunoGen’s Elahere, the only antibody-drug conjugate approved for platinum-resistant ovarian cancer in the US, will produce better than anticipated sales for the first quarter of 2023, CEO Mark Enyedy hinted in a recent interview.

• Source: Shutterstock

“We will have revenue for the first quarter at the end of April and the launch is exceeding our expectations,” ImmunoGen, Inc. CEO Mark Enyedy as told In Vivo, Scrip’s sister publication, speaking about Elahere, the only antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer in the US

Elahere (mirvetuximab soravtansine) received accelerated approval from the US Food and Drug Administration on 14 November 2022 for the treatment...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

 

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

 

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

More from Business

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By 

The Swiss giant has been talking to the US government about selling medicines directly to patients.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.